BHT-3009

N/A

Report date: 2022/11/25 17:18:40

Base Information

Drug NameBHT-3009
Drug Alias NameBHT-300904BHT-3009
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine
Mechanisms of ActionT lymphocytes inhibitorsImmunosuppressants
TargetsNot applicable
Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBayhill Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBayhill Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A